Spark Therapeutics, Inc. ("Spark") is a developer of gene therapy treatments, which treat debilitating genetic diseases.

According to Complaint, this action stems from a proposed transaction announced on February 25, 2019, pursuant to which Spark will be acquired by Roche Holdings, Inc. and 022019 Merger Subsidiary, Inc.

On February 22, 2019, Spark’s Board of Directors caused the Company to enter into an agreement and plan of merger with Roche. Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer to acquire all of Spark’s outstanding common stock for $114.50 per share in cash. The Tender Offer is set to expire on April 3, 2019.

On March 7, 2019, defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on September 5, 2019.